Patents Assigned to Mercator Medsystems, Inc.
-
Patent number: 11813249Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: January 14, 2021Date of Patent: November 14, 2023Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 10576063Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: May 25, 2018Date of Patent: March 3, 2020Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 10441747Abstract: Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.Type: GrantFiled: January 26, 2015Date of Patent: October 15, 2019Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 9884013Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.Type: GrantFiled: May 15, 2015Date of Patent: February 6, 2018Assignees: Abraxis BioScience, LLC, Mercator MedSystems, Inc.Inventors: Kirk Seward, Neil P. Desai
-
Patent number: 9789276Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.Type: GrantFiled: October 25, 2013Date of Patent: October 17, 2017Assignee: Mercator Medsystems, Inc.Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
-
Patent number: 9199065Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: GrantFiled: March 18, 2015Date of Patent: December 1, 2015Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 9149497Abstract: Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.Type: GrantFiled: September 26, 2008Date of Patent: October 6, 2015Assignee: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Robert Cafferata
-
Patent number: 9011879Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: GrantFiled: May 16, 2013Date of Patent: April 21, 2015Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Publication number: 20140303569Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: Mercator MedSystems, Inc.Inventors: Kirk Patrick SEWARD, Lynn Mateel BARR, Judith Carol WILBER, Robert CAFFERATA
-
Publication number: 20140296279Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.Type: ApplicationFiled: April 27, 2012Publication date: October 2, 2014Applicants: Mercator MedSystems, Inc., Abraxis BioScience, LLCInventors: Kirk Seward, Neil P. Desai
-
Patent number: 8721590Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.Type: GrantFiled: August 31, 2011Date of Patent: May 13, 2014Assignee: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
-
Patent number: 8708995Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.Type: GrantFiled: May 28, 2010Date of Patent: April 29, 2014Assignee: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Judith Carol Wilber, Robert Cafferata
-
Publication number: 20140107478Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.Type: ApplicationFiled: October 25, 2013Publication date: April 17, 2014Applicant: Mercator MedSystems, Inc.Inventors: Kirk Patrick SEWARD, Isidro M. GANDIONCO, David GANDIONCO
-
Patent number: 8465752Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: GrantFiled: April 22, 2010Date of Patent: June 18, 2013Assignee: Mercator Medsystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 8399443Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: GrantFiled: April 22, 2010Date of Patent: March 19, 2013Assignee: Mercator Medsystems, Inc.Inventor: Kirk Patrick Seward
-
Publication number: 20110313353Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.Type: ApplicationFiled: August 31, 2011Publication date: December 22, 2011Applicant: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
-
Patent number: 8016786Abstract: A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.Type: GrantFiled: February 23, 2010Date of Patent: September 13, 2011Assignee: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Isidro M. Gandionco, David Gandionco
-
Publication number: 20110104061Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: ApplicationFiled: April 22, 2010Publication date: May 5, 2011Applicant: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Publication number: 20110104060Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: ApplicationFiled: April 22, 2010Publication date: May 5, 2011Applicant: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Publication number: 20100305546Abstract: Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.Type: ApplicationFiled: May 28, 2010Publication date: December 2, 2010Applicant: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Judith Carol Wilber, Robert Cafferata